Table 4.
Fecal microbiota transplantation intervention studies. MPTP: 1-Methyl-4-phenil-1,2,3,6-tetrahydropyridine.
| PD Model | Intervention | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Author | Model | Toxic | Dose | Duration | Administration | Dose | Duration | Administration | Results |
| [48] | C57BL/6 mice | Rotenone | 30 mg/kg/day | 28 days | Oral (gavage) | 100 µL/day (100 mg/mL) |
14 days | Oral (gavage) | Reversal of the gut microbiota dysbiosis and protection from inflammation mediated by LPS-TLR4 signaling pathway. |
| [49] | MPTP | 20 mg/kg/day | 35 days | Intraperitoneal | 200 µL/day (108 CFU/mL) |
14 days | Intraperitoneal | Reversal of the gut microbial dysfunction and neuroprotection. Reduced activation of microglia and astrocytes in the SN and reduced expression levels of GSK3β, IL-1β, inducible nitric oxide synthase, and phosphorylated PTEN in the SN. | |
| [50] | 15 mg/kg | 7 days | 200 μL/day (108 CFU/mL) |
7 days | Oral (gavage) | Augmentation of neurogenesis, improvement in motor function, and restoration of dopaminergic neurons and neurotransmitters. | |||
| [51] | 30 mg/kg/day | 5 days | 200 μL/day (1 g/15 mL) |
10 days | Regulation of mitochondrial oxidative resistance to neuroinflammation and rescue of nigrostriatal pericyte loss and BBB disruption. | ||||